Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research

NCT06155565 | Not Yet Recruiting

• 1 other identifier: 65829005
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical trials, specifically focused on anxiety disorder, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.

Conditions

Anxiety Disorder

Keywords

anxiety disorder

Outcome Measures

Primary Outcomes (2)

• Number of anxiety disorder patients who decide to enroll in a clinical research

  3 months

• Rate of anxiety disorder patients who remain in clinical trial to trial completion

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with anxiety disorder who are actively considering enrolling in a clinical study for said condition, but have not yet completed enrollment and randomization.

You may qualify if:

• Aged ≥ 18 years old
• Diagnosis of anxiety disorder
• Able to comprehend the investigational nature of the protocol and provide informed consent

You may not qualify if:

• Female patients who are currently pregnant or nursing
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Inability to perform regular electronic reporting

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Study Sites (1)

Power Life Sciences

San Francisco, California, 94107, United States

Location

Related Publications (3)

• Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec 27;328(24):2431-2445. doi: 10.1001/jama.2022.22744.

  PMID: 36573969 BACKGROUND

• Yee A, Ng CG, Seng LH. Vortioxetine Treatment for Anxiety Disorder: A Meta-Analysis Study. Curr Drug Targets. 2018;19(12):1412-1423. doi: 10.2174/1389450118666171117131151.

  PMID: 29149828 BACKGROUND

• Liao J, Kang J, Li F, Li Q, Wang J, Tang Q, Mao N, Li S, Xie X. A cross-sectional study on the association of anxiety and depression with the disease activity of systemic lupus erythematosus. BMC Psychiatry. 2022 Sep 5;22(1):591. doi: 10.1186/s12888-022-04236-z.

  PMID: 36064377 BACKGROUND

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

415-900-4227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2023
• First Posted: December 4, 2023
• Study Start: December 1, 2024
• Primary Completion: December 1, 2025
• Study Completion (Estimated): December 1, 2026
• Last Updated: December 4, 2023

Record last verified: 2023-11

Locations

US (1)